S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Helix BioPharma (HBP) Stock Forecast, Price & News

+0.01 (+5.00%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
27,850 shs
Average Volume
30,044 shs
Market Capitalization
C$32.34 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive HBP News and Ratings via Email

Sign-up to receive the latest news and ratings for Helix BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Helix BioPharma logo

About Helix BioPharma

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.


Helix BioPharma Corp.: Helix Announces Board Resignation
Stocks in play: Helix BioPharma Corp
See More Headlines

Industry, Sector and Symbol

Year Founded

Sales & Book Value

Annual Sales
Cash Flow
C$0.00 per share
Book Value
C($0.03) per share


Pretax Margin




Free Float
Market Cap
C$32.34 million

Company Calendar

Last Earnings
Next Earnings (Estimated)


Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Helix BioPharma (TSE:HBP) Frequently Asked Questions

When is Helix BioPharma's next earnings date?

Helix BioPharma is scheduled to release its next quarterly earnings announcement on Monday, June 13th 2022.
View our earnings forecast for Helix BioPharma

How were Helix BioPharma's earnings last quarter?

Helix BioPharma Corp. (TSE:HBP) posted its earnings results on Wednesday, March, 16th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter.
View Helix BioPharma's earnings history

Who are Helix BioPharma's key executives?
Helix BioPharma's management team includes the following people:
  • Mr. Artur Gabor, CEO & Chairman (Age 62, Pay $60k)
  • Mr. Photios Michalargias C.A., CPA, CA, CPA, Chief Financial Officer (Age 59, Pay $285.87k)
What other stocks do shareholders of Helix BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Helix BioPharma investors own include Lakeland Industries (LAKE), Liquidia (LQDA), Ovintiv (OVV), SIG (SHI), Green Organic Dutchman (TGOD), Zynerba Pharmaceuticals (ZYNE), American Airlines Group (AAL), Aurora Cannabis (ACB), Apollo Investment (AINV) and Aphria (APHA).

What is Helix BioPharma's stock symbol?

Helix BioPharma trades on the Toronto Stock Exchange (TSX) under the ticker symbol "HBP."

How do I buy shares of Helix BioPharma?

Shares of HBP and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Helix BioPharma's stock price today?

One share of HBP stock can currently be purchased for approximately C$0.21.

How much money does Helix BioPharma make?

Helix BioPharma has a market capitalization of C$32.34 million.

How many employees does Helix BioPharma have?

Helix BioPharma employs 10 workers across the globe.

What is Helix BioPharma's official website?

The official website for Helix BioPharma is www.helixbiopharma.com.

How can I contact Helix BioPharma?

Helix BioPharma's mailing address is 21 St Clair Ave E Suite 1100, TORONTO, ON M4T 1L9, Canada. The biopharmaceutical company can be reached via phone at +1-416-9253232.

This page was last updated on 5/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.